Corporate Presentation
|
|
- Arleen Reed
- 6 years ago
- Views:
Transcription
1 Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y
2 Forward Looking Statements / Safe Harbor This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding future results of the operations of ARMO BioSciences, Inc. ( We, ARMO or the Company ), including financial position, strategy, and plans and ARMO s expectations for future operations, are forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the timing and success of preclinical studies and clinical trials conducted by ARMO; the ability to obtain and maintain regulatory approval of ARMO s product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing ARMO s product candidates; ARMO s ability to obtain and maintain intellectual property protection for ARMO s product candidates; ARMO s anticipated growth strategies; ARMO s expectations regarding competition; the anticipated trends and challenges in ARMO s business and the market in which we operate; ARMO s ability to attract or retain key personnel; the size and growth of the potential markets for ARMO s product candidates and the ability to serve those markets; the rate and degree of market acceptance of any of ARMO s product candidates; ARMO s ability to establish and maintain development partnerships; ARMO s expectations regarding federal, state and foreign regulatory requirements; regulatory developments in the United States and foreign countries; and ARMO s use and sufficiency of its cash resources. Moreover, ARMO operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for ARMO s management to predict all risks, nor can ARMO assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied. Except as required by law, neither ARMO nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. ARMO undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in ARMO s expectations. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities. C O N F I D E N T I A L a n d P R O P R I E T A R Y 2
3 Investment Highlights IO Focused Business Model Clinical stage immuno-oncology (IO) company Portfolio of IO product candidates Strong and experienced management team IPO closed January 30, $147 million in total gross proceeds AM0010 (Pegilodecakin) Phase 1/1b clinical trial treated 350+ patients in multiple solid tumors - Objective responses as a single agent in cutaneous T-cell lymphoma, melanoma and RCC - Clinical efficacy seen in PDAC, NSCLC, RCC, CRC & melanoma - Improves tolerability of checkpoint and chemo regimens Phase 3 clinical trial (SEQUOIA) +/- FOLFOX in PDAC actively enrolling - Orphan drug (US & EU) and Fast Track designations received in Second interim analysis could provide basis for BLA filing as early as 2020 Two Phase 2 clinical trials (CYPRESS 1 & 2) in NSCLC enrolling patients in Q Initial data read outs on both studies expected in late 2018 Initiate RCC clinical trial with AM0010 in 2H 2018 Additional Portfolio Depth AM0001 anti-pd-1 antibody moving into Phase 1 clinical trial by Y/E Option to optimize commercial potential by combining with internal assets Additional pre-clinical IO assets such as IL-12, IL-15 and anti-lag-3 in development C O N F I D E N T I A L a n d P R O P R I E T A R Y 3
4 Management Team Peter Van Vlasselaer, PhD President and CEO Co-Founder Joseph Leveque, MD Chief Medical Officer Herb Cross Chief Financial Officer Martin Oft, MD VP Pre-Clinical and Clinical Development Co-Founder Russ Kawahata, PhD VP Technical Operations C O N F I D E N T I A L a n d P R O P R I E T A R Y 4
5 Pipeline and Development Timeline Product Candidate Indication / Combination (Clinical Trial) Current Development Stage Preclinical Pre-IND IND Phase 1 Phase 1b Phase 2 Phase 3 Development Status PDAC/FOLFOX (SEQUOIA) Enrollment of 1st patient in early 2017 First interim analysis expected in early 2018 AM0010 (PEG-IL-10) NSCLC/Anti-PD-1 (CYPRESS 1 and 2) RCC/Anti-PD-1 Enrollment of 1st patient in Phase 2 clinical trial(s) planned for 1H 2018 Evaluating Phase 2 clinical trial(s) Melanoma and Other Solid Tumor Indications Evaluating Phase 2 clinical trials in additional indications (e.g. CRC, melanoma, TNBC) AM0001 (Anti-PD-1 mab) All Tumor Indications Initiation of Phase 1 clinical trial in 2018 AM0015 (IL-15) All Tumor Indications Pre-Clinical POC AM0012 (IL-12) All Tumor Indications Pre-Clinical POC AM0003 (Anti-LAG-3 mab) All Tumor Indications Pre-Clinical POC C O N F I D E N T I A L a n d P R O P R I E T A R Y 5
6 AM0010 Mechanism of Action C O N F I D E N T I A L a n d P R O P R I E T A R Y 6
7 Rationale for AM0010 in Immuno-Oncology Intra-tumoral CD8 T cell deficiency and chronic inflammation are linked to a poor prognosis in cancer patients Efficient anti-tumor immune therapy may benefit from drugs that combine anti-inflammatory and CD8 T cell activation properties Anti-Inflammatory CD8 T cell activation IL-10 Biology IL-10 Biology AM0010 Systemic and sustained reduction of inflammatory molecules such as IL-12p40, IL-17, IL-23 and TGF-ß Stimulation of T cell activating cytokines IFNγ, IL-18, IL-7, IL-4, GM-CSF C O N F I D E N T I A L a n d P R O P R I E T A R Y 7
8 AM0010 Increases Intra-Tumoral CD8 + T Cell Numbers AM0010 Monotherapy Increases the Number of Intra-Tumoral PD-1 + CD8 + Granzyme + T Cells in Phase 1/1b Colorectal Cancer Patient Pre Treatment Day 60 of Treatment CRC Liver Metastasis Pyknotic Tumor Cells Tumor Infiltrating Cytotoxic PD-1 + CD8 + T Cells (TILs) Tumor Cells Granzyme B CD8 Note: Granzyme B CD8 staining C O N F I D E N T I A L a n d P R O P R I E T A R Y 8
9 AM0010 Clinical Trials Phase 1/1b C O N F I D E N T I A L a n d P R O P R I E T A R Y 9
10 Phase 1/1b Data Guides Registration Strategy Establish novel combinations and sequentials with IO therapies (e.g. PD-1/PD-L1 inhibitors) with emerging IO therapies with non-io therapies (e.g. SOC targeted therapies, chemotherapies) Focus on patient populations with unmet medical need none and low tumor PD-L1 expression low tumor mutational burden disseminated disease (e.g. liver) Exploit anti-inflammatory properties limit treatment-related adverse events, both immune and non-immune in origin potentiate efficacy by advancing dose intensity reduce morbidity associated with off-target effects C O N F I D E N T I A L a n d P R O P R I E T A R Y 10
11 AM0010 Phase 1/1b Clinical Trial Over 350 Patients Enrolled Across 14 Different Cancers Monotherapy Dose Expansion CRC 4 th Line AM0010 Combo-Therapy Dose Escalation PDAC 2 nd Line FOLFOX + AM0010 SEQUOIA - Phase 3 PDAC 2 nd Line FOLFOX + AM0010 Monotherapy Dose Escalation Melanoma >2 nd Line Anti-PD-1 Refractory Pembro + AM0010 Combo-Therapy Dose Escalation with Anti-PD-1 Nivo/Pembro NSCLC >2 nd Line Nivo + AM0010 RCC >2 nd Line Nivo or Pembro + AM0010 CYPRESS (1 and 2) 1. NSCLC 1 st Line w/ Pembro +/- AM0010 in PD-L1 H 2. NSCLC 2 nd Line w/ Nivo +/- AM0010 in PD-L1 L C O N F I D E N T I A L a n d P R O P R I E T A R Y 11
12 AM0010 Clinical and Regulatory Summary Assessed AM0010 s tolerability, mechanism of action and preliminary efficacy in an ongoing Phase 1/1b clinical trial - Over 350 cancer patients treated across 14 different types of cancer and several treatment settings Monotherapy Combined with checkpoint inhibitors (nivolumab, pembrolizumab) Combined with SOC chemotherapies (FOLFOX) - Well tolerated as a single agent and in combination with chemo and anti-pd-1 SOC therapy - Most common TrAEs being anemia, thrombocytopenia, fatigue and fever - AM0010 potentially reduces immune-related complications when used in combination with checkpoint inhibitors - Durable responses in PDAC, NSCLC, CRC and Melanoma* with data maturing in other indications * As measured by overall survival benefit for AM0010 alone or in combination with standard of care therapies in these populations with advanced stage diseases that are longer than those observed historically based on the medical literature in comparable or earlier stage populations. C O N F I D E N T I A L a n d P R O P R I E T A R Y 12
13 AM0010 Clinical Trials PDAC AM0010 received Orphan Drug Designation (US and EU) and Fast Track Designation in 2016 C O N F I D E N T I A L a n d P R O P R I E T A R Y 13
14 AM0010 in PDAC Phase 1/1b Clinical Trial Data AM0010 AM PDAC FOLFOX Monotherapy FOLFOX** N (Evaluable) N (ITT) Prior Therapies (Median) Prior Therapies (Range) NA (2-6) (1-5) ORR % *** CR + PR CR % DCR 36% 53% * 74% CR + PR + SD PFS (Months - Median) OS (Months - Median) OS (Landmark - One Year) 18.5% 22.7% 42.9% AM0010 data as of Zaanan et al., BMC 2014 (FOLFOX in 2L PDAC) * Based on 8 of 15 evaluable subjects with stable disease at 2 months ** Median follow-up for subjects still alive is ~20 months *** Includes two (2) CRs and one (1) PR with 100% tumor reduction DCR = Disease Control Rate; ORR = Objective Response Rate; CR = Complete Response; PFS = Progression Free Survival; OS = Overall Survival C O N F I D E N T I A L a n d P R O P R I E T A R Y 14
15 AM0010/FOLFOX Combo in PDAC Phase 1/1b Data AM0010/FOLFOX Combo Therapy Has Improved OS in Late Stage Patients (Median 3 rd LOT; Range 2 nd -6 th ) Who Progressed on a Prior Gemcitabine Containing Regimen 4.3 months mos and 18.5% 1-y OS with FOLFOX monotherapy in Zaanan et al Refs: Phase 2 (Zaanan et al, BMC, 2014) Note: AM0010/FOLOFX data as of C O N F I D E N T I A L a n d P R O P R I E T A R Y 15
16 AM0010/FOLFOX Combo is Well Tolerated in PDAC FOLFOX cycles (Median 3 rd LOT) compared to: - Oettle et al.; JCO 2014 (CONKO3) - Zaanan et al.; BMC 2014 (FIRGEM) Rate of Neuropathy (treatment related and unrelated) Study Grade 1/2 Grade 3/4 Reference OFF 2 nd LOT 38.2% 4% Oettle JCO 2014 FOLFOX 2 nd LOT 44% 7% Zaanan BMC 2014 FOLFOX 2 nd LOT NA 4.1% Gill JCO 2016 AM FOLFOX 16% 0% Current data* *AM0010 data as of NA: not available C O N F I D E N T I A L a n d P R O P R I E T A R Y 16
17 AM0010 in PDAC Phase 3 Clinical Trial Design (SEQUOIA) Arm 1 AM FOLFOX Advanced metastatic pancreatic cancer 2 nd line Tx after one prior gemcitabine regimen N=566 1:1 Randomization Interim Analysis 1 n = 60 DMC Recommendation Continue Trial Discontinue Trial Interim Analysis 2 (70% of 393 deaths) DMC Recommendation Stop for superiority Complete Trial Discontinue Trial Final Analysis (393 deaths) FOLFOX Arm 2 Proposed Timing of Events st Interim - Go/No-Go decision 2 nd Interim analysis Potential basis for BLA filing C O N F I D E N T I A L a n d P R O P R I E T A R Y 17
18 AM0010 Clinical Trials - NSCLC C O N F I D E N T I A L a n d P R O P R I E T A R Y 18
19 AM0010 in NSCLC Phase 1/1b Clinical Trial Data Anti-PD-1 mab AM0010 AM AM NSCLC Monotherapy Monotherapy Nivolumab Pembrolizumab N (Evaluable) NA 7 * 22 5 ** N (ITT) NA 9 * 29 5 ** Prior Therapies (Median) Prior Therapies (Range) NA (1-7) (1-3) (0-5) ORR 19% - 41% 40% CR + PR CR DCR 41% 57% 82% 100% CR + PR + SD PFS (Months - Median) NR 11.0 OS (Months - Median) NR (1) TBD (2) (1) Clinical trial in progress. Numbers as of October 29, Median follow-up 17.5 months (range ) (2) OS reached, To Be Disclosed at an upcoming scientific conference. As of October 29, 2017, median follow-up was 31.2 months (range ) Garon et al., NEJM 2015 (pembrolizumab in 2L NSCLC) * Only five (5) subjects available for testing, all of which were PD-L1 negative ** Only four (4) subjects available for testing, all of which were PD-L1 negative AM0010 data as of DCR = Disease Control Rate; ORR = Objective Response Rate; CR = Complete Response; PFS = Progression Free Survival; OS = Overall Survival; NR = Not reached C O N F I D E N T I A L a n d P R O P R I E T A R Y 19
20 AM0010 in NSCLC Indications of Efficacy Regardless of PD-L1 Status Anti-PD-1 mab AM ORR by PD-L1 Expression Monotherapy Anti-PD-1 mab* All 19% 41% (Responses/N) (96/495) (11/27) > 50% 44% 80% (Responses/N) (25/57) (4/5) 1-49% 16% 67% (Responses/N) (12/77) (2/3) < 1% 9% 33% (Responses/N) (2/22) (4/12) Twenty (20) of 27 subjects had PD-L1 testing Garon et al., NEJM 2015 * Includes both nivolumab and pembrolizumab treated subjects C O N F I D E N T I A L a n d P R O P R I E T A R Y 20
21 AM0010 in NSCLC Indications of Efficacy Regardless of TMB and PD-L1 Status NSCLC Tumor Mutational Burden and PD-L1 Expression in Pegilodecakin plus Nivolumab Treated Patients (n=10) Notes: 1. Includes all patients available for TMB and PD-L1 status testing 2. High/Low TMB stratification (243) used in Carbone et al, NEJM 2017 C O N F I D E N T I A L a n d P R O P R I E T A R Y 21
22 AM Pembrolizumab or Nivolumab Reduces Measurable Secondary Liver Lesions Change in Measurable Secondary Liver Lesions in NSCLC on AM0010 in Combination with Pembrolizumab or Nivolumab (n=18) Pre-Treatment 7 Months of Treatment (-81%) A total of 8/27 patients had liver metastasis 5/8 patients had a partial response (63% ORR) 8 patients had a combined total number of 18 target lesions in the liver 16/18 metastasis showed reduction in size during combo therapy 14/16 lesions showed >50% reduction in size C O N F I D E N T I A L a n d P R O P R I E T A R Y 22
23 AM Nivolumab Potentially Reduces Clinically Meaningful Immune-Related Complications Immune-Related Adverse Events (iraes) AM Nivolumab (N) 2 AM N 3 N N = = 144 N N = = 134 N N = = Event % % % Rash % % % Pruritus % % 2 6.9% Fatigue % 7 5.2% % Appetite Loss % 4 3.0% % Vitiligo 0 0.0% 2 1.5% 0 0.0% Pneumonitis 0 0.0% 6 4.5% 1 3.4% Adrenal Insufficiency 0 0.0% 0 0.0% 1 3.4% Thyroiditis/Hypothyroiditis 1 0.7% % 1 3.4% Hypophysitis 0 0.0% 1 0.7% 0 0.0% Mucocytis 1 0.7% 3 2.2% 0 0.0% Colitis 0 0.0% % 0 0.0% Hepatitis 0 0.0% 5 3.7% 0 0.0% Cholangitis 2 1.4% 2 1.5% 0 0.0% Polyarthritis 0 0.0% 1 0.7% 0 0.0% Myasthenia Gravis 0 0.0% 1 0.7% 0 0.0% Optic Neuritis 0 0.0% 0 0.0% 1 3.4% irae rate excluding rash, pruritus, fatigue and appetite loss 2.8% 30.6% * 13.8% (1) Includes phase 1/1b clinical trial monotherapy subjects from all indications (2) Haratani et al. JAMA Onc: pp E1-5 ( ); NSCLC patients (3) Includes only NSCLC patients *Assumes one irae per patient C O N F I D E N T I A L a n d P R O P R I E T A R Y 23
24 AM0010 in NSCLC CYPRESS 1 Clinical Design N ~50 AM Pembrolizumab ORR Stage IV / Metastatic WT NSCLC 1L PD-L1 H N ~100 R NSC 70 / SC 30 Limit in Each Arm Treatment to Progression Crossover Stratify by Histology Mutational Burden PS 0-1 Histology Agnostic N ~50 Pembrolizumab ORR C O N F I D E N T I A L a n d P R O P R I E T A R Y 24
25 AM0010 in NSCLC CYPRESS 2 Clinical Design N ~50 AM Nivolumab ORR Stage IV / Metastatic WT NSCLC 2L PD-L1 L PS 0-1 Histology Agnostic No Exposure to Immune-Based Therapies N ~100 R NSC 70 / SC 30 Limit in Each Arm N ~50 Nivolumab Treatment to Progression Crossover Stratify by Histology Mutational Burden Smoking Status ORR C O N F I D E N T I A L a n d P R O P R I E T A R Y 25
26 AM0010 Clinical Trials - RCC C O N F I D E N T I A L a n d P R O P R I E T A R Y 26
27 AM0010 in RCC Phase 1/1b Clinical Data Summary Nivolumab AM0010 AM AM RCC Monotherapy Monotherapy Nivolumab Pembrolizumab N (Evaluable) N (ITT) Prior Therapies (Median) Prior Therapies (Range) NA (0-7) (1-3) (0-5) ORR 20%-22% 25% 39% 50% CR + PR CR less than 1% % * DCR 57%-65% 56% 81% 100% CR + PR + SD PFS (Months - Median) NR 16.7 OS (Months - Median) NR (1) NR (2) (1) Clinical trial in progress. Numbers as of October 29, Median follow-up 13.8 months (range ) (2) Clinical trial in progress. Numbers as of October 29, Median follow-up 29.4 months (range ) Motzer et al., NEJM 2015 (nivolumab in 2L RCC) * Two (2) partial responses with 100% reduction of measurable disease AM0010 data as of DCR = Disease Control Rate; ORR = Objective Response Rate; CR = Complete Response; PFS = Progression Free Survival; OS = Overall Survival; NR = Not reached C O N F I D E N T I A L a n d P R O P R I E T A R Y 27
28 Other AM0010 Clinical Trials C O N F I D E N T I A L a n d P R O P R I E T A R Y 28
29 Melanoma & CRC Phase 1/1b Clinical Data Summary We observed encouraging survival in a number of additional tumors in our Ph1/1b clinical trial - AM0010 +pembrolizumab cohort, (n=25) Melanoma - mos of 16.7 months observed in patients resistant or refractory to anti-pd-1/ipilimumab - 1 year survival rate of 57% - Recent trial of ipilimumab+pembrolizumab in patients with a similar profile demonstrated a mos of 8 months 1 - AM0010 monotherapy cohort, (n=27) CRC - mos of 11 months observed in patients who had failed a median number of four prior therapies - Recent trial of trifluridine/tiperacil in a similar patient population demonstrated a mos of 7.1 months 2 (1) Kirchberger et al., EJC 2016 (2) Mayer et al., NEJM 2015 C O N F I D E N T I A L a n d P R O P R I E T A R Y 29
30 Other Immunotherapy Assets C O N F I D E N T I A L a n d P R O P R I E T A R Y 30
31 Robust Pipeline of Immunotherapy Assets AM0001 anti-pd-1 checkpoint inhibitor, currently undergoing Investigational New Drug Application (IND) enabling studies AM0015 IL-15, a pre-ind stage product candidate has demonstrated preclinical antitumor responses that are additive with AM0010 AM0012 IL-12, currently in preclinical studies AM0003 anti-lag-3 checkpoint inhibitor, undergoing pre-ind enabling studies C O N F I D E N T I A L a n d P R O P R I E T A R Y 31
32 ARMO Summary C O N F I D E N T I A L a n d P R O P R I E T A R Y 32
33 Finance & IP Strong Balance Sheet Strong Financial Position - $177M in private capital raised pre-ipo - IPO closed January $147M in gross proceeds Cash and cash equivalents balance of ~$67M at September 30, 2017 No debt outstanding AM0010 IP Strong Composition of Matter (COM) portfolio - Base COM claims through 2029 with possibility for extension up to 2034 Orphan designation also provides 7-year market exclusivity C O N F I D E N T I A L a n d P R O P R I E T A R Y 33
34 Key Corporate Milestones Continue data read out from Phase 1/1b (survival in PDAC, RCC, NSCLC, Melanoma and CRC as well as PFS in select cohorts) 1H 2018 Initiate CYPRESS 1 NSCLC study 1L pembrolizumab +/- AM0010 Initiate CYPRESS 2 NSCLC study 2L nivolumab +/- AM st interim analysis (safety) in AM0010 SEQUOIA PDAC study Preliminary data readouts from CYPRESS 1 NSCLC study in late H 2018 Preliminary data readouts from CYPRESS 2 NSCLC study in late 2018 Initiate RCC clinical trial with AM0010 Initiate AM0001 (anti-pd-1) clinical trial Potential pivotal NSCLC studies potentially commencing (expected 2019) Preliminary data readout from RCC study (2H 2019) 2 nd interim analysis (safety + efficacy) in SEQUOIA PDAC study (expected 2020) C O N F I D E N T I A L a n d P R O P R I E T A R Y 34
35 Investment Highlights IO Focused Business Model Clinical stage immuno-oncology (IO) company Portfolio of IO product candidates Strong and experienced management team IPO closed January 30, $147 million in total gross proceeds AM0010 (Pegilodecakin) Phase 1/1b clinical trial treated 350+ patients in multiple solid tumors - Objective responses as a single agent in cutaneous T-cell lymphoma, melanoma and RCC - Clinical efficacy seen in PDAC, NSCLC, RCC, CRC & melanoma - Improves tolerability of checkpoint and chemo regimens Phase 3 clinical trial (SEQUOIA) +/- FOLFOX in PDAC actively enrolling - Orphan drug (US & EU) and Fast Track designations received in Second interim analysis could provide basis for BLA filing as early as 2020 Two Phase 2 clinical trials (CYPRESS 1 & 2) in NSCLC enrolling patients in Q Initial data read outs on both studies expected in late 2018 Initiate RCC clinical trial with AM0010 in 2H 2018 Additional Portfolio Depth AM0001 anti-pd-1 antibody moving into Phase 1 clinical trial by Y/E Option to optimize commercial potential by combining with internal assets Additional pre-clinical IO assets such as IL-12, IL-15 and anti-lag-3 in development C O N F I D E N T I A L a n d P R O P R I E T A R Y 35
Determined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationCalithera Biosciences
Calithera Biosciences March 2019 Forward-Looking Statements This presentation and the accompanying oral commentary contain forward looking statements for purposes of the safe harbor provisions of the Private
More informationCalithera Biosciences. January 2019
Calithera Biosciences January 2019 Forward-Looking Statements This presentation and the accompanying oral commentary contain forward looking statements for purposes of the safe harbor provisions of the
More informationCorporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018
Corporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More information3Q 2016 presentation
Arming the patient s immune system to fight cancer 3Q 2016 presentation 17 November 2016 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since
More informationIdera Pharmaceuticals
Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning
More informationASCO 2018 Investor Meeting
ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationCalithera Biosciences. September 2018
Calithera Biosciences September 2018 Forward-Looking Statements This presentation and the accompanying oral commentary contain forward looking statements for purposes of the safe harbor provisions of the
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 1Q 2018 EARNINGS PRESENTATION MAY 2018 1 Forward-looking statements disclosure This presentation contains
More informationJEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationBank of America Merrill Lynch 2018 Health Care Conference. Reinventing Therapeutic Antibodies for the Treatment of Cancer
Bank of America Merrill Lynch 2018 Health Care Conference Reinventing Therapeutic Antibodies for the Treatment of Cancer May 17, 2018 1 Forward Looking Statements Special Note Regarding Forward-Looking
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2017 EARNINGS PRESENTATION MARCH 2018 1 Forward-looking statements disclosure This presentation contains
More informationSyndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab)
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) Ongoing ENCORE 601 biomarker analyses suggest enhanced clinical benefit in subpopulation
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE
ESMO 2016 * Investor Meeting October 9, 2016 *European Society of Medical Oncology, October 7-11, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationIL-10: Less Inflammation and More CD8 + Cytotoxicity
Efficacy of PEGylated Human IL-10 (AM0010) in Combination with anti-pd-1 Blockade in Patients (pts) with Metastatic Renal Cell Carcinoma (mrcc): A phase 1b Trial Aung Naing, Jeffrey R. Infante, Deborah
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationDelcath Investor Presentation (OTCQB: DCTH)
Delcath Investor Presentation (OTCQB: DCTH) December 2018 1 DELCATH SYSTEMS, INC Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationFrédéric Triebel MD, PhD World Immunotherapy Congress Basel, October 30, 2018
Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab Frédéric Triebel MD, PhD World Immunotherapy Congress
More informationMOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014
Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationArming the patient s immune system to fight cancer
Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationRexahn Pharmaceuticals Overview
Rexahn Pharmaceuticals Overview May 2018 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn s actual results may differ
More informationINTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2014 Q2 AUGUST 28, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 2.6 million doses IMVAMUNE delivered to the SNS during H1 (0.9 million in Q2) Increased contribution
More informationImmune and Tumor Responses to PEGylated Human IL-10 (AM0010, Pegilodecakin) alone or in combination with immune checkpoint blockade
Immune and Tumor Responses to PEGylated Human IL-10 (AM0010, Pegilodecakin) alone or in combination with immune checkpoint blockade Aung Naing, Deborah J. Wong, Jeffrey R. Infante, Raid Aljumaily, Kyriakos
More information2019 ASCO-SITC. Nektar Therapeutics Investor & Analyst Call. March 1, 2019
Nektar Therapeutics Investor & Analyst Call March 1, 2019 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of
More informationARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the
More informationInvestor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.
Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation
More informationCorporate Presentation. October 2017
AEPP Breakthrough technology for women s cancers Corporate Presentation October 2017 Oncolix 2017 1 Safe Harbor Certain of the statements and the projections set forth in this presentation constitute forward-looking
More informationCorporate Overview. June 2018 NASDAQ:FPRX
Corporate Overview June 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationQ Financial Update November 6, 2018 NASDAQ:FPRX
Q3 2018 Financial Update November 6, 2018 NASDAQ:FPRX 2 Forward-Looking Statements Disclaimer Forward-looking statements contained in this presentation include statements regarding (i) the timing of initiation,
More informationCorporate Presentation June Curis, Inc All Rights Reserved
Corporate Presentation June 2018 Curis, Inc. 2018 All Rights Reserved Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ( we, us, or the Company
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationReimagining Cancer Treatment. Determined to realize a future in which people with cancer live longer and better than ever before
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Cantor Fitzgerald 2nd Annual Healthcare Conference July 13, 2016 Forward-Looking
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationCowen Annual Healthcare Conference. March 2018
Cowen Annual Healthcare Conference March 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO Forward-Looking Statements This
More informationJefferies 2018 Healthcare Conference. June 6, 2018
Jefferies 2018 Healthcare Conference z June 6, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of ongoing
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 1 Forward-looking statements disclosure This presentation contains forward-looking
More informationNew Data from Ongoing Melanoma Study and Clinical Development Strategy Update
New Data from Ongoing Melanoma Study and Clinical Development Strategy Update Webcast - 29 th / 30 th May 2018 (ASX: IMM, NASDAQ: IMMP) Notice: Forward Looking Statements The purpose of the presentation
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationHighlights from AACR 2015: The Emerging Potential of Immunotherapeutic Approaches in Non-Small Cell Lung Cancer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer
November 26, 2018 CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer VANCOUVER, Washington, Nov. 26, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc.
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationAttached from the following page is the press release made by BMS for your information.
September 28, 2015 Opdivo (nivolumab) Demonstrates Superior Overall Survival in a Phase 3 Trial Compared to Standard of Care in Patients with Previously Treated Advanced Renal Cell Carcinoma (PRINCETON,
More informationFor personal use only
The global leader in developing LAG-3 therapeutics BioCentury 25th Annual NewsMakers in the Biotech Industry Conference New York 7 th September 2018 (ASX: IMM, NASDAQ: IMMP) Notice: Forward Looking Statements
More informationSAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018
SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAFE HARBOR STATEMENT Savara Inc. ( Savara or the Company ) cautions you that statements in this presentation that are not a description of historical
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationCOMPANY OVERVIEW. June CytomX Therapeutics, Inc.
COMPANY OVERVIEW June 2016 2016 CytomX Therapeutics, Inc. Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationIdera Pharmaceuticals 36 th Annual J.P. Morgan Healthcare Conference Idera Pharmaceuticals
Idera Pharmaceuticals 36 th Annual J.P. Morgan Healthcare Conference Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning of
More informationClinical: Ipilimumab (MDX-010) Update and Next Steps
Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 1 Forward-looking statements disclosure This presentation contains
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationCANCER VACCINES THE NEXT WAVE IN IMMUNO-ONCOLOGY
CANCER VACCINES THE NEXT WAVE IN IMMUNO-ONCOLOGY Peter Skorpil VP Business Development peter.skorpil@targovax.com Cutting Edge Oslo 2016-10-18 www.targovax.com 1 Important notice and disclaimer This report
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationFifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More information